依托三酯
医学
安慰剂
萘普生
塞来昔布
骨关节炎
内科学
荟萃分析
萘丁美酮
布洛芬
优势比
入射(几何)
胃肠病学
麻醉
药理学
非甾体
替代医学
病理
物理
光学
作者
Dam Kim,Soo‐Kyung Cho,Seoung Wan Nam,Hyun Hee Kwon,Sun‐Young Jung,Chan Hong Jeon,Seul Gi Im,Dalho Kim,Eun Jin Jang,Yoon‐Kyoung Sung
标识
DOI:10.4078/jrd.2017.24.5.293
摘要
Objective.To estimate the cardiovascular (CV) and gastrointestinal (GI) risks of etoricoxib in the treatment of osteoarthritis (OA) compared to a placebo and other non-steroidal anti-inflammatory drugs (NSAIDs).Methods.A systematic review of randomized, controlled trials (RCTs) of etoricoxib were performed.Bayesian network meta-analysis was used over a duration of 12 weeks.The incidence of CV and GI events for a duration ≥26 weeks were also tabulated and presented using descriptive statistics.Results.From this search, 10 studies were identified.Of these, 6 and 5 RCTs that measured the CV and GI events at 12 weeks were included in meta-analysis.They showed that etoricoxib did not increase the CV events compared to the placebo or NSAIDs during the 12 week period (odds ratio [OR]=0.59compared to celecoxib, OR=0.89 with ibuprofen, OR=0.70 with placebo, and OR=2.16 with naproxen).The risk of GI events was comparable to that of most comparators, with the exception of naproxen, which had a significantly lower risk of GI events (OR=0.18)during the 12 week period.For a duration ≥26 weeks, the incidence of CV and GI events with etoricoxib increased with increasing duration.Conclusion.Etoricoxib is an alternative short-term treatment option for OA, showing comparable CV and GI complications to other NSAIDs.Nevertheless, further studies will be needed to elucidate the long-term safety of etoricoxib in the treatment of OA. (
科研通智能强力驱动
Strongly Powered by AbleSci AI